Comparative Pharmacology
Head-to-head clinical analysis: CAPASTAT SULFATE versus PARASAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPASTAT SULFATE versus PARASAL.
CAPASTAT SULFATE vs PARASAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Capastat sulfate (capreomycin) is a cyclic polypeptide antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, interfering with initiation and elongation steps.
Uncertain; may involve inhibition of prostaglandin synthesis in the CNS, weak inhibition of COX-1 and COX-2, and activation of TRPA1 channels.
15 mg/kg (max 1 g) intramuscularly daily for 60-120 days.
4 g (8 capsules or 2 sachets) orally every 6 hours; maximum 16 g per day.
None Documented
None Documented
3-6 hours; prolonged to 12-24 hours in renal impairment; negligible hepatic metabolism
Terminal half-life: 10-15 hours in adults with normal renal function; prolonged to 20-30 hours in renal impairment.
Primarily renal (80-90% as unchanged drug via glomerular filtration); minor fecal (10-20%)
Renal: 50-60% as unchanged drug; biliary/fecal: 20-30% as metabolites; total recovery: >80% within 24 hours.
Category C
Category C
Antituberculosis Agent
Antituberculosis Agent